Minerva Neurosciences reported $54.95M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 204.92M 57.48M
Adma Biologics ADMA:US $ 69.5M 18.42M
AstraZeneca AZN:LN 5762M 567M
Biocryst Pharmaceuticals BCRX:US $ 395.5M 108.88M
Bristol Myers Squibb BMY:US $ 12369M 1610M
Dynavax Technologies DVAX:US $ 179.42M 256.77M
Eli Lilly And LLY:US $ 2459.2M 1359.3M
Esperion Therapeutics ESPR:US $ 150.36M 58.53M
GlaxoSmithKline GSK:LN 10967M 6693M
Halozyme Therapeutics HALO:US $ 117.84M 0.88M
Marinus Pharmaceuticals MRNS:US $ 126.32M 3.39M
Merk MRK:US $ 8556M 460M
Minerva Neurosciences NERV:US $ 54.95M 5.81M
Novartis NOVN:VX SF 13852M 1445M
Novavax NVAX:US $ 1570.95M 1209.13M
Takeda 4502:JP Y 849695M 125354M
Vanda Pharmaceuticals VNDA:US $ 66.93M 14.86M